Navigation Links
Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
Date:3/1/2012

VANCOUVER, British Columbia, March 1, 2012 /PRNewswire/ -- Enox Biopharma, Inc. (VANCOUVER, BC.) CEO, John C. Rewcastle, Ph.D., will present at the IN360 Investment in Innovation Conference on Thursday, March 1 at 10:35 AM EST. The conference is being held at the Ritz Carlton Hotel in Orlando.

The IN360 is the newest iteration of the successful IN3 meeting series, hosted by Elsevier. It is a medical device technology forum and networking meeting. The foundation of the meeting is presentations from emerging companies like Enox Biopharma to audiences principally composed of larger medical device manufacturers and venture capitalists.

Dr. Rewcastle will present Enox's technology whose foundation is the patent protected ability to embed nitric oxide into polymers which renders medical devices antimicrobial. This innovative technology is a potential solution to one of the most significant burdens on medical systems worldwide: hospital acquired infections.

"In the United States alone, it is estimated that $30-45 billion dollars per year are spent due to hospital acquired infections," said Enox CEO John Rewcastle. "Enox is uniquely positioned to address this problem by inhibiting the formation of infections seeded when a medical device such as a catheter is inserted into the body. With nitric oxide as the mechanism of action, devices incorporating our technology will not have issues such as non-effectiveness or antibiotic resistance as do competitive products."

"The IN360 meeting is a uniquely effective environment provide exposure and constructive interaction between emerging and established medical device companies," continued Rewcastle. "Enox will be especially attractive to potential strategic partners in attendance. Our breakthrough technology has the potential of meeting the needs of hospitals worldwide who are currently underserved by existing infection prevention technology."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Enox Biopharma, Inc. Expands Its Technology to Cover the Wound Care Market
2. PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015
3. Enox Biopharma, Inc. Appoints Dr. John Rewcastle as CEO
4. Sinobiopharma, Inc. Appoints New Director of Marketing
5. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
6. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
7. Regeneron Announces March 2012 Investor Conference Presentations
8. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
9. OncoSec to Present at 10th Annual BioPartnering North America
10. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
11. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/10/2017)... CALIFORNIA (PRWEB) , ... October 10, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation for ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):